Anti-metastatic effect of curcumin analog pentagamaboronon-0-fructose (PGB-0-F) against 4T1 breast cancer cells

Abstract

Development of a chemotherapeutic agent and boron carrying pharmaceutical based on triple-negative breast cancer is important due to its metastatic progression. Metastases are often more dangerous than the primary tumor and they are responsible for 90% of all cancer deaths. The purpose of this study was to explore the anti-metastatic activities of the PGB-0 complex with fructose (PGB-0-F) against 4T1 breast cancer cells. A scratch wound healing assay was carried out to determine the migration inhibition ability of PGB-0-F, while MMP-9 expression was analysed using gelatin zymography. The testing of anti-migration activity showed that PGB-0-F inhibited in 4T1 cells, whereas the gelatin zymography assay revealed a suppression of MMP-9 expression. PGB-0-F inhibited closure on 4T1 metastatic breast cancer cells line compared with the control. PGB-0-F decreased the MMP-9 expression level compared with the control. Based on these results, PGB-0-F has the potential to be developed as a chemotherapeutic agent, and especially as an anti-metastatic agent.

The Role of BNCT in Breast Cancer Treatment

“…Irradiation of neutron beam to the boron compound causes the boron-10 atoms to split to Li nuclei and alpha radiation (He nuclei) which only give intracell effects within cancer cells [8,9,11,[31][32][33][34] as shown in Fig. 6 [35,36].…”

Synthesis, Characterization, Cytotoxicity Study and Docking Studies of New Fused-pyrazoline Derivatives derived from Bis-Chalcones Against Breast Cancer cells

“…Most importantly, curcumin has been reported to selectively kill tumor cells but not the normal cells [14,15]. However, due to its active methylene moiety, the clinical efficacy of curcumin is limited by its low stability at pH above 6.5 [16]. Therefore, curcumin analogs have been synthesized by modifying the methylene group into either cyclopentanone or cyclohexanone to improve their stability in biological medium as shown in Figure 2 [15][16].…”